ArticleESC heart failure2026
Ambulatory low cardiac output state in heart failure: characteristics and outcomes.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAmbulatory low cardiac output state (LCOS) is a known but poorly described heart failure (HF) phenotype. We aimed to investigate the prevalence, clinical markers, and prognostic importance of ambulatory LCOS.
methodsConsecutive ambulatory patients with HF and reduced left ventricular ejection fraction referred for advanced HF assessment were included. All patients underwent right heart catheterization. Patients with LCOS defined as a cardiac index <1.8 L/min/m2 were compared to patients without LCOS.
resultsIn total, 618 patients were included. The mean ± SD age was 52.5 ± 12.5 years, and 78% were male. Low cardiac output state was present in 116 patients (19% [95% CI 16 to 22%]). Patients with LCOS presented with more advanced symptoms, lower systolic blood pressure and LVEF, higher N-terminal pro-B-type natriuretic peptide levels, and were less likely to receive treatment with renin-angiotensin system inhibitors (RASi) compared with patients without LCOS. Absence of RASi therapy was strongly associated with LCOS, odds ratio 2.34 [95% CI 1.44 to 3.74], P < .001. While liver function markers were more elevated in patients with LCOS, renal function was similar between groups. Over a median follow-up of five years, LCOS was independently associated with mortality, hazard ratio 1.86 [95% 1.32 to 2.62], P < .001 (adjusted for age, sex, and advanced therapy).
conclusionLCOS was observed in 19% of ambulatory patients and was strongly associated with mortality, independent of left-sided filling pressures and advanced therapies. Among other factors, the absence of RASi therapy was highly predictive of LCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.